Bayer’s Strong Q1 Masks a Legal Tightrope as Supreme Court Weighs Glyphosate’s Fate

Bayer's Q1 2026 earnings beat forecasts driven by Crop Science, but a €2.32B cash drain from legal settlements and a pending Supreme Court ruling on glyphosate litigation overshadow gains.

Bayer delivered a stronger-than-expected start to 2026, but the real share-price catalyst remains locked in a courtroom. The life-science group’s first-quarter numbers beat analyst forecasts across the board, driven by a rebound in its agricultural division and a one-off licensing gain. Yet the euphoria is tempered by a €2.32 billion cash drain from legal settlements and the looming June decision from the US Supreme Court that could reshape the entire glyphosate litigation landscape.

The stock closed Tuesday at €38.59, up 3.41% on the day. Over the past month it still sits 5.39% lower, though the 12-month gain of 55.64% testifies to the recovery hopes already priced in. Investors are walking a fine line: they cheer the operational momentum but remain acutely aware that the legal overhang could tighten or loosen dramatically within weeks.

Crop Science Drives the Quarter

Revenue rose 4.1% on a currency- and portfolio-adjusted basis to €13.405 billion, comfortably above the subdued expectations many analysts had set. The star was Crop Science, where sales grew 6.8% in currency-adjusted terms to €7.558 billion, fuelled by soybean seed and trait licensing. A previously disclosed settlement with Corteva added €448 million to the top line, providing a tailwind that masked some of the currency headwinds hitting the group.

The leverage flowed straight to profit. Group EBITDA before special items improved 9% to €4.453 billion, with Crop Science’s figure leaping 17.9% to €3.014 billion thanks to cost efficiencies and lower manufacturing expenses. At the net level, earnings hit €2.763 billion — more than double the prior year — helped by the €250 million sale of the global Avelox business. On a per-share basis, adjusted EPS reached €2.71, beating the consensus estimate of €2.28 by a wide margin.

The Cash Drain That Won’t Go Away

The strong income statement, however, stands in stark contrast to the balance sheet. Free cash flow plunged to minus €2.320 billion, almost entirely because of €2.002 billion in payouts related to PCB and glyphosate litigation. That pushed net financial debt up 9% to €32.518 billion by the end of March. Bayer continues to forecast a negative free cash flow for the full year, underscoring how the legal bills are siphoning cash that could otherwise fund operations or acquisitions.

CEO Bill Anderson is pressing ahead with the “Dynamic Shared Ownership” restructuring, having already eliminated more than 12,000 positions. The aim is to flatten hierarchies and speed decision-making, especially in the pharmaceuticals division, where patent expiries on key drugs like Xarelto are weighing on growth. Last week Bayer announced a deal to buy Perfuse Therapeutics for up to $2.45 billion, securing rights to a glaucoma and diabetic retinopathy candidate. It is a targeted bet to fill the revenue hole, but the cost adds to the financial strain.

Dual Legal Deadlines Converge in June

The calendar is now dominated by two intertwined legal events. First, plaintiffs have until early June to opt out of the proposed $7.25 billion class-action settlement covering glyphosate claims. If enough reject the deal, the accord could collapse. A final court hearing for approval is scheduled for July. Anderson cautioned that it may take “several more weeks” to resolve all objections, dampening hopes for a quick clean exit.

Second, the Supreme Court is expected to rule in June on the “John Durnell” case, which tests whether federal pesticide labels pre-empt state-level failure-to-warn claims. Bayer argues that EPA approval must prevail; without that pre-emption, the company warned of “regulatory anarchy.” A favourable ruling could sharply cap future liabilities, while an adverse one would keep the litigation taps open for years.

For now, Bayer is a story of two realities: an operating business that is beating expectations and a legal legacy that is devouring cash and clouding the outlook. The June decisions will determine whether the operational strength can finally translate into sustained share-price momentum — or whether the courtroom battles continue to hold the stock hostage.